Clinical and
pre-clinical applications of PET/CT in both humans and small
animals, with particular emphasis to oncology and respiratory
medicine. Particular interest is devoted to the study of PET/CT
employment in highly malignant tumours (e. g. lymphoma, breast, colon,
prostate, lung carcinoma, sarcomas, testicular tumours) for staging, early
assessment to therapy response, identification of the primary
tumour site in patients with known secondary lesions, early
detection of disease relapse after therapy.
Clinical
applications of PET/CT with 18F-FDG and non-FDG tracers
(68Ga-DOTANOC, 18F-DOPA 11C-Colina, 11C-Acetato, 11C-Metionina, 68Ga-PSMA). In particolar employment
of 68Ga-DOTANOC for the assessment of patients with neuroendocrine
tumours. Employment of PET/CT in the study of inflammaotory
disorders and lung disorders.
Clinical research:
- imaging of neuroendocrine tumours employing 68Ga-DOTA-NOC
PET/CT
- imaging of neuroendocrine tumours employing18F-DOPA PET/CT
- imaging of neuroendocrine tumours employing 18F-FDG PET/CT
(low grade forms or low expression of somatostatin receptors)
- 68Ga-DOTA-NOC PET/CT in patients with idiopathic pulmonary
fibrosis
- PET/CT imaging of sarcoidosis (disease extension, response to
therapy, detection of relapse)
- Role of 11C-Choline PET/CT in prostate tumours
- 18F-FDG PET/CT in staging, restaging, evaluation of response
to treatment, follow-up of high grade tumours (e.g. colo-rectal
carcinoma, lung cancer, gastric cancer, multiple mieloma, breast
cancer, ovarian cancer, GIST, breast cancer, melanoma, Hodgkin and
non-Hodgkin lymphoma)
- 18F-FDG PET/CT in the assessment of patients with tubercolosis
and fever of unknown origin
- 18F-FDG PET/CT in the clinical management of patients with
testicular tumours
- 18F-FDG PET/CT imaging of patients with spondilodyscitis
- Clinical applications of novel PET radiopharmaceuticals
Pre-clinical imaging: role of small animal PET in the assessment
of murine models of human tumours (Hodgkin and non-Hodgkin
lymphoma, lung cancer, neuroblastoma, rhabdomyosarcomas),
miocardiac hypoxia, obesity, gynecolagical infection.
